SUPPORT CANADIANS LIVING WITH CANCER
Treatment of stage III penile cancer
The following are treatment options for stage III penile cancer. The types of treatments given are based on the unique needs of the person with cancer.
Surgery is the primary treatment for stage III penile cancer. The types of surgery are:
- partial or total penectomy
- removal of lymph nodes
- Lymph nodes in the groin may be removed at the same time as a penectomy if they are known to contain cancer.
- Surgery to remove the lymph nodes may be followed by radiation therapy.
- scrotectomy (removal of the scrotum) or orchiectomy (removal of the testicles)
- The scrotum, testicles or both may need to be removed if the cancer has spread to these structures.
- This is only done in very advanced cases of penile cancer.
- pelvic exenteration
- This surgery may be done if cancer has spread to the bladder.
Radiation therapy may be offered for stage III penile cancer. The type of radiation therapy is external beam radiation therapy. Radiation therapy may be given:
- instead of surgery
- after surgery (adjuvantadjuvantTreatment given in addition to the first-line therapy (the first or standard treatment) to help reduce the risk of a disease (such as cancer) coming back (recurring). radiation therapy)
- with chemotherapy (chemoradiation)
The role of chemotherapy in treating penile cancer is still evolving. It may be offered for stage III penile cancer. Chemotherapy may be given, with or without radiation therapy, either:
- before surgery (neoadjuvantneoadjuvantTreatment given to shrink a tumour before the first-line therapy (the first or standard treatment), which is usually surgery. chemotherapy or chemoradiation)
- after surgery (adjuvant chemotherapy or chemoradiation)
Men with penile cancer may be offered the opportunity to participate in clinical trials. For more information, go to clinical trials.
Clinical trial discovery improves quality of life
A clinical trial led by the Society’s NCIC Clinical Trials group found that men with prostate cancer who are treated with intermittent courses of hormone therapy live as long as those receiving continuous therapy.